Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernewsroom.regeneron.com
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 148 followers
Last updated 6 days ago
6 days ago
If approved, Dupixent would be the first targeted medicine in the EU...
7 days ago
Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science...
9 days ago
Approval in adults and children aged 6 years and older supported by...
14 days ago
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that...
21 days ago
TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ...
23 days ago
36 abstracts to be presented across Regeneron -invented therapies, including first-time Phase...
about 1 month ago
New presentations include final 64-week results from the Phase 3 QUASAR trial...
about 1 month ago
Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter...
about 1 month ago
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery...
2 months ago
TARRYTOWN, N.Y. , Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
2 months ago
Approval based on global Phase 3 program in children demonstrating Dupixent significantly...
2 months ago
TARRYTOWN, N.Y. , Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...